Elderly Men Creating Huge Requirement for BPH Treatment Drugs and Devices

As elderly men are highly susceptible to this urinary tract disease, a boom in the geriatric population will drive the BPH treatment market growth during the forecast period (2021–2030).
ALHAMBRA, Calif. - June 15, 2022 - PRLog -- Benign prostatic hyperplasia (BPH) or prostate gland enlargement is caused due to urinary tract infections, bladder or kidney stones, prostatitis, urethral stricture, bladder or prostate cancer, and scarring in the bladder neck caused due to previous surgeries. The common signs and symptoms of BPH include frequent urination, nocturia, difficulty in initiating urination, dribble at the end of urination, and inability to empty the bladder. This disease is highly prevalent among men above the age of 40 years. Nearly one-third of the male population experience moderate-to-severe symptoms of BPH by 60 years of age.

Browse In-depth Benign Prostatic Hyperplasia Treatment Market Revenue Forecast Report (https://www.psmarketresearch.com/market-analysis/benign-prostatic-hyperplasia-treatment-bph-market)

According to P&S Intelligence, North America was the largest consumer of BPH treatment drugs and devices in 2020, globally. This is due to the booming geriatric population, which is highly prone to BPH and other diseases related to the lower urinary tract. Moreover, the increasing number of innovations in BPH devices and mounting awareness about urinary tract diseases will also fuel the adoption of BPH treatment solutions in the coming years. Additionally, the high reimbursement coverage being offered by BPH devices producing companies will also augment the usage of these devices in the region in the foreseeable future.

Whereas, the Asia-Pacific (APAC) BPH treatment market is expected to showcase the fastest growth during the forecast period, due to the growing aging population, rising cases of BPH and associated disorders, and mounting investments being made in the healthcare sector in the region. As per the United Nations Population Fund (UNFPA), one in every four people in APAC would be above 60 years of age, by 2050. As BPH is extremely common among people above 50 years of age, the surging population of the elderly will give an impetus to the market growth in the region in the forecast years.

Therefore, the booming geriatric population and the rising cases of BPH will create a huge requirement for BPH treatment drugs and devices in the upcoming years.

Pramod Kumar
Email:***@psmarketresearch.com Email Verified
Tags:Bph Treatment
Location:Alhambra - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
P&S Intelligence PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share